NAFLD prevalence and severity in overweight and obese populations
- PMID: 36400096
- DOI: 10.1016/S2468-1253(22)00375-2
NAFLD prevalence and severity in overweight and obese populations
Conflict of interest statement
SMAF holds a senior clinical investigator fellowship from the Research Foundation Flanders (1802154N). SMAF's institution has received grants from Astellas, Falk Pharma, Genfit, Gilead Sciences, GlympsBio, Janssens Pharmaceutica, Inventiva, Merck Sharp & Dome, Pfizer, and Roche. SMAF has served as consultant for AbbVie, Actelion, Aelin Therapeutics, AgomAb, Aligos Therapeutics, Allergan, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Coherus, Echosens, Eisai, Enyo, Galapagos, Galmed, Genetech, Genfit, Gilead Sciences, Intercept, Inventiva, Janssens Pharmaceutica, Julius Clinical, Madrigal, Medimmune, Merck Sharp & Dome, NGM Bio, Novartis, Novo Nordisk, Promethera, and Roche. SMAF has been lecturer for AbbVie, Allergan, Bayer, Eisai, Genfit, Gilead Sciences, Janssens Cilag, Intercept, Inventiva, Merck Sharp & Dome, Novo Nordisk, Promethera, and Siemens. ED has served as a consultant for NovoNordisk, Ely Lilly, and Boehringer Ingelheim.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
